We report herein a detailed study concerning the impact of different bioconjugation and
nanoformulation strategies on the in vitro targeting ability of peptide-decorated squalenoyl …

Chemotherapy for pancreatic cancer is hampered by the tumor's physio-pathological
complexity. Here we show a targeted nanomedicine using a new ligand, the CKAAKN …

Based on their tunable physicochemical properties and the possibility of producing cell-
specific platforms through surface modification with functional biomolecules, nanoparticles …

Targeted use of nanoparticles in vitro, in cells, and in vivo requires nanoparticle surface
functionalization. Moieties that can be used for such a purpose include small molecules as …

Peptide–nanoparticle conjugates (PNCs) have recently emerged as a versatile tool for
biomedical applications. Synergism between the two promising classes of materials allows …

Protein-conjugated nanoparticles have the potential to precisely deliver therapeutics to
target sites in the body by specifically binding to cell surface receptors. To maximize …

One of the major weaknesses of therapeutic peptides is their sensitivity to degradation by
proteolytic enzymes in vivo. Gold nanoparticles (GNPs) are a good carrier for therapeutic …

Combined therapy with gemcitabine and tyrosine-kinase inhibitors (ie, sunitinib) has already
demonstrated important benefits in pancreatic cancer treatment. Further therapeutic …

The use of peptides to mediate the delivery and uptake of nanoparticle (NP) materials by
mammalian cells has grown significantly over the past 10 years. This area of research has …

The relationship between the positioning of ligands on the surface of nanoparticles and the
structural features of nanoconjugates has been underestimated for a long time, albeit of …